Annual Direct Medical Costs of Diabetic Foot Disease in Brazil: A Cost of Illness Study
AbstractThe aim of this study was to estimate the annual costs for the treatment of diabetic foot disease (DFD) in Brazil. We conducted a cost-of-illness study of DFD in 2014, while considering the Brazilian Public Healthcare System (SUS) perspective. Direct medical costs of outpatient management and inpatient care were considered. For outpatient costs, a panel of experts was convened from which utilization of healthcare services for the management of DFD was obtained. When considering the range of syndromes included in the DFD spectrum, we developed four well-defined hypothetical DFD cases: (1) peripheral neuropathy without ulcer, (2) non-infected foot ulcer, (3) infected foot ulcer, and (4) clinical management of amputated patients. Quantities of each healthcare service was then multiplied by their respective unit costs obtained from national price listings. We then developed a decision analytic tree to estimate nationwide costs of DFD in Brazil, while taking into the account the estimated cost per case and considering epidemiologic parameters obtained from a national survey, secondary data, and the literature. For inpatient care, ICD10 codes related to DFD were identified and costs of hospitalizations due to osteomyelitis, amputations, and other selected DFD related conditions were obtained from a nationwide hospitalization database. Direct medical costs of DFD in Brazil was estimated considering the 2014 purchasing power parity (PPP) (1 Int$ = 1.748 BRL). We estimated that the annual direct medical costs of DFD in 2014 was Int$ 361 million, which denotes 0.31% of public health expenses for this period. Of the total, Int$ 27.7 million (13%) was for inpatient, and Int$ 333.5 million (87%) for outpatient care. Despite using different methodologies to estimate outpatient and inpatient costs related to DFD, this is the first study to assess the overall economic burden of DFD in Brazil, while considering all of its syndromes and both outpatients and inpatients. Although we have various reasons to believe that the hospital costs are underestimated, the estimated DFD burden is significant. As such, public health preventive strategies to reduce DFD related morbidity and mortality and costs are of utmost importance. View Full-Text
Share & Cite This Article
Toscano, C.M.; Sugita, T.H.; Rosa, M.Q.M.; Pedrosa, H.C.; Rosa, R.S.; Bahia, L.R. Annual Direct Medical Costs of Diabetic Foot Disease in Brazil: A Cost of Illness Study. Int. J. Environ. Res. Public Health 2018, 15, 89.
Toscano CM, Sugita TH, Rosa MQM, Pedrosa HC, Rosa RS, Bahia LR. Annual Direct Medical Costs of Diabetic Foot Disease in Brazil: A Cost of Illness Study. International Journal of Environmental Research and Public Health. 2018; 15(1):89.Chicago/Turabian Style
Toscano, Cristiana M.; Sugita, Tatiana H.; Rosa, Michelle Q.M.; Pedrosa, Hermelinda C.; Rosa, Roger S.; Bahia, Luciana R. 2018. "Annual Direct Medical Costs of Diabetic Foot Disease in Brazil: A Cost of Illness Study." Int. J. Environ. Res. Public Health 15, no. 1: 89.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.